Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Spector

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
The Pediatric Infectious Disease Journal|June 3, 1999
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials GroupK McIntosh, E Cooper, J Xu, et al.
The Journal of Pediatrics|October 27, 1998
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study TeamR E McKinney, G M Johnson, K Stanley, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
The Journal of Infectious Diseases|March 18, 2000
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 CollaboratorsW Borkowsky, D Wara, T Fenton, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
HIV Clinical Trials|September 30, 2005
The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapyD A Wohl, M A Kendall, S Owens, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
The Pediatric Infectious Disease Journal|June 3, 1999
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials GroupK McIntosh, E Cooper, J Xu, et al.
The Journal of Pediatrics|October 27, 1998
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study TeamR E McKinney, G M Johnson, K Stanley, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
The Journal of Infectious Diseases|March 18, 2000
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 CollaboratorsW Borkowsky, D Wara, T Fenton, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
HIV Clinical Trials|September 30, 2005
The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapyD A Wohl, M A Kendall, S Owens, et al.
Pageof 20